Tag Archives: MYGN

Top 5 Warren Buffett Stocks To Watch Right Now

In 2016 Q3, Facebook (NSDQ:FB)reported quarter over quarter and year over year growth in revenue, net income and earnings per share. Following the earnings release, Facebook’s share price is now down over 8%. Some investors may believe the price drop is a buying opportunity (buy the dip); they should not. Even with Facebook’s strong Q3 performance, I believe FB stock is overvalued and investors should stay away.

In the analysis below I will discuss two operational head winds that will cause Facebook’s revenue and net income growth to stagnate in the future. The third paragraph will look at why earnings per share may actually decrease.

DAU and MAU Growth

Facebook defines DAU as daily active users and MAU as monthly active users. During the earnings release the company shared the following graphics on the geographic composition on DAU and MAU growth.

Top 5 Warren Buffett Stocks To Watch Right Now: Tekla Healthcare Opportunies Fund(THQ)

Tekla Healthcare Opportunities Fund is a non-diversified closed-end management investment company. The Fund’s investment objective is to seek current income and long-term capital appreciation through investments in the United States and non-United States companies in the healthcare industry, including equity securities, debt securities, and pooled investment vehicles. The Fund invests in securities of public and private companies. The Fund may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, if these securities would comprise 10% or less of Managed Assets. The Fund’s investment portfolio includes information technology, healthcare, consumer discretionary, telecommunications, industrials, consumer staples, financials, utilities, energy and materials. Tekla Capital Management LLC is the investment adviser to the Fund. Advisors’ Opinion:

  • [By Ethan Ryder]

    Tekla Healthcare Opportunities Fund (NYSE:THQ) declared a monthly dividend on Monday, June 11th, Wall Street Journal reports. Investors of record on Wednesday, June 20th will be paid a dividend of 0.1125 per share on Friday, June 29th. This represents a $1.35 dividend on an annualized basis and a dividend yield of 7.72%. The ex-dividend date of this dividend is Tuesday, June 19th.

Top 5 Warren Buffett Stocks To Watch Right Now: Tiffany & Co.(TIF)

Tiffany & Co. (the “Registrant”) is a holding company that operates through its subsidiary companies (collectively, the “Company”). The Registrant’s principal subsidiary is Tiffany and Company (“Tiffany”). Charles Lewis Tiffany founded Tiffany’s business in 1837. He incorporated Tiffany in New York in 1868. The Registrant acquired Tiffany in 1984 and completed the initial public offering of the Registrant’s Common Stock in 1987. The Registrant, through its subsidiaries, sells jewelry and other items that it manufactures or has made by others to its specifications.
FINANCIAL INFORMATION ABOUT REPORTABLE SEGMENTS
The Company’s segment information for the fiscal years ended January 31, 2016, 2015 and 2014 is reported in “Item 8. Financial Statements and Supplementary Data – Note P – Segment Information.   Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Tiffany & Co (NYSE:TIF)Q42018 Earnings Conference CallMarch 22, 2019, 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Bell & Brown Wealth Advisors LLC lifted its position in shares of Tiffany & Co. (NYSE:TIF) by 143.2% during the 4th quarter, Holdings Channel reports. The firm owned 14,895 shares of the specialty retailer’s stock after buying an additional 8,771 shares during the quarter. Bell & Brown Wealth Advisors LLC’s holdings in Tiffany & Co. were worth $1,199,000 at the end of the most recent quarter.

  • [By Leo Sun]

    LVMH’s growth in China defies the notion that its economic slowdown is impacting the consumption of luxury goods. Tiffany & Co. (NYSE:TIF)also recently reported “double-digit” sales growth in China during the holidays.

Top 5 Warren Buffett Stocks To Watch Right Now: Dawson Geophysical Company(DWSN)

Dawson Geophysical Company provides onshore seismic data acquisition and processing services in the United States. It acquires and processes 2-D, 3-D, and multi-component seismic data for its clients, including oil and gas companies, and independent oil and gas operators, as well as the providers of multi-client data libraries. The 2-D method involves the collection of seismic data to generate a single plane of subsurface seismic data. The 3-D method creates a volume of seismic data, which produces precise images of the earth?s subsurface. As of September 30, 2011, the company operated 14 3-D seismic data acquisition crews in the lower 48 states, as well as a seismic data processing center. Dawson Geophysical Company was founded in 1952 and is headquartered in Midland, Texas with additional offices in Houston, Denver, Oklahoma City, and Pittsburgh.

Advisors’ Opinion:

  • [By Max Byerly]

    Dawson Geophysical (NASDAQ:DWSN) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday.

  • [By Logan Wallace]

    Dawson Geophysical (NASDAQ:DWSN) was upgraded by stock analysts at TheStreet from a “d+” rating to a “c-” rating in a research note issued on Monday.

Top 5 Warren Buffett Stocks To Watch Right Now: Myriad Genetics, Inc.(MYGN)

Myriad Genetics, Inc. (Myriad), incorporated on November 6, 1992, is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Myriad offers diagnostic tests for a range of diseases, such as Myriad myRisk Hereditary Cancer test for hereditary breast cancer, hereditary ovarian cancer, hereditary pancreatic cancer, hereditary uterine (endometrial) cancer and hereditary colon cancer; Myriad myPlan Lung Cancer test for lung cancer; Myriad myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis (RA).

Molecular Diagnostic Testing

The Company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins. Myriad’s primary molecular diagnostic tests include myRisk Hereditary Cancer, a deoxyribonucleic acid (DNA) sequencing test for assessing the risks for hereditary cancers, such as breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer; BRACAnalysis, a DNA sequencing test for assessing the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx ! , a DNA sequencing test for use as a companion diagnostic with the poly (ADP-ribose) polymerase (PARP) inhibitor LynparzaTM (olaparib); Tumor BRACAnalysis CDx, a DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum-based chemotherapy agents and PARP inhibitors; COLARIS, a DNA sequencing test for assessing the risk of colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for assessing the risk of colorectal cancer; Vectra DA, a protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a ribonucleic acid (RNA) expression test for assessing the aggressiveness of prostate cancer; EndoPredict, an RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, an RNA expression test for diagnosing melanoma, and myPlan Lung Cancer, an RNA expression test for assessing the aggressiveness of lung cancer.

Pharmaceutical and Clinical Services

The Company provides a range of pharmaceutical and clinical services. Through its subsidiary, Myriad RBM, Inc., Myriad provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology and medical research industries utilizing its multiplexed immunoassay technology. The Company also owns Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, located approximately 15 miles from the Company’s European laboratories in Munich, Germany. The Company’s technology enables it to screen sets of well-characterized clinical samples from both diseased and non-diseased populations against its menu of biomarkers.

Advisors’ Opinion:

  • [By Maxx Chatsko]

    February was a great month for genetic testing stocks. Shares of Invitae (NYSE:NVTA) paced the pack with a monthly gain of 42.9%, according to data provided by S&P Global Market Intelligence. That was followed by NeoGenomics (NASDAQ:NEO) and Myriad Genetics (NASDAQ:MYGN), which rose 17.9% and 10.1%, respectively.

  • [By Maxx Chatsko]

    Despite all the progress, Invitae is still the least mature business among its publicly traded peers, including Genomic Health (NASDAQ:GHDX) and Myriad Genetics (NASDAQ:MYGN). Here’s how it compares to its closest competitors:

  • [By Ethan Ryder]

    ILLEGAL ACTIVITY NOTICE: “Myriad Genetics (MYGN) Releases Q3 Earnings Guidance” was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at www.tickerreport.com/banking-finance/4128676/myriad-genetics-mygn-releases-q3-earnings-guidance.html.

  • [By Motley Fool Transcribers]

    Myriad Genetics Inc (NASDAQ:MYGN)Q2 2019 Earnings Conference CallFeb. 05, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Warren Buffett Stocks To Watch Right Now: Moneygram International, Inc.(MGI)

MoneyGram International, Inc., together with its subsidiaries, provides money transfer and payment services in the United States and internationally. The company operates in two segments, Global Funds Transfer and Financial Paper Products. The Global Funds Transfer segment provides money transfer and bill payment services primarily to unbanked and underbanked consumers. Its bill payment services allow consumers to make bill payments, pay routine bills, or load and reload prepaid debit cards with cash at an agent location, company-operated locations, or through moneygram.com with a credit or debit card, as well as through kiosks, ATMs, prepaid cards, and direct-to-bank account products. The Financial Paper Products segment provides money orders to consumers through its retail agents and financial institutions; and offers official check outsourcing services for financial institutions. This segment sells its money orders under the MoneyGram brand and on a private label or co-branded basis with retail and financial institution agents. MoneyGram International, Inc. was founded in 1926 and is headquartered in Dallas, Texas.

Advisors’ Opinion:

  • [By Motley Fool Transcribing]

    MoneyGram International (NASDAQ:MGI) Q4 2018 Earnings Conference CallFeb. 11, 2019 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Moneygram International (MGI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Cardtronics (NASDAQ: MGI) and Moneygram International (NASDAQ:MGI) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.